Doxorubicin is contra-indicated in patients who have a marked myelosuppression (e.g. induced by previous anti-tumour treatment), in pre-existing or acute cardiac insufficiency or in patients who have previously received the maximum cumulative dose of doxorubicin or daunorubicin.
The presence of buccal ulceration; this may be preceded by premonitory buccal burning sensations and repetition of treatment in the presence of this symptom is not advised.
During pregnancy and breast feeding.
Hypersensitivity to doxorubicin, chemically related products or any other excipient.
Doxorubicin should not be used intravesically for the treatment of bladder carcinoma in patients with urethral stenosis who can not be catheterised.
The intravesical route of administration should not be attempted in patients with invasive tumours that have penetrated the bladder wall, urinary tract infections or inflammatory conditions of the bladder.